Loading
A phase 1/2 trial of AB-2100 in renal cell carcinoma, run by Arsenal Biosciences, Inc., active and no longer recruiting.
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) is a phase 1/2 interventional study registered as NCT06245915 by Arsenal Biosciences, Inc., with 37 participants enrolled, started 2024-02-26 and due to reach its primary completion in 2026-03-31. Interventions recorded: AB-2100.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Arsenal Biosciences and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/